TL;DR
This paper introduces REAP, a novel computational tool that uses robust beta regression to more accurately estimate drug potency from dose-response data, especially when the data contains extreme values. This improved estimation leads to more reliable drug discovery and development by providing narrower confidence intervals and higher statistical power.
What Problem Does This Paper Address?
In drug discovery, understanding how a compound's potency changes with its dose is crucial. The standard method for this, the median-effect equation, relies on linear regression after a logit transformation. However, real-world experimental data often includes "extreme responses" – values very close to 0% or 100% effect. These outliers can significantly skew the results of the standard method, leading to inaccurate estimations of drug potency (like IC50 or Hill coefficients) and reduced statistical power. Simply removing these extreme values is often not an option, as they can represent biologically relevant phenomena. This paper addresses the need for a more robust and accurate method to estimate dose-response relationships in the presence of such challenging data.
Methods
The core of this work is the development of a novel approach based on robust beta regression. Unlike standard linear regression, beta regression is designed to model continuous variables bounded between 0 and 1, which is ideal for representing biological responses like cell viability or inhibition. The authors further enhance this by incorporating a minimum density power divergence (MDPDE) estimation method. This technique is specifically designed to be robust against outliers, minimizing the impact of extreme data points. To make this method accessible, they developed REAP (Robust and Efficient Assessment of Potency), a user-friendly, web-based application built using the Shiny package in R. REAP allows researchers to upload their data, perform robust dose-response curve estimation, and obtain key statistics and visualizations.
Datasets
The paper utilizes simulated datasets for extensive testing of their proposed method under various scenarios, including the presence of extreme values and heteroscedasticity. Additionally, they demonstrate the application of REAP using two real-world datasets:
- B-cell lymphoma data: This dataset involves evaluating the dose-response of auranofin across different MCL cell lines.
- SARS-CoV-2 data: This dataset comprises dose-response curves for several antiviral drugs tested against the SARS-CoV-2 virus.
Key Insights and Ideas
- Extreme values are a major problem: Even small deviations in experimental data, especially at the extremes of the dose-response curve, can lead to substantial biases in standard estimation methods.
- Deleting outliers is not a solution: Removing extreme data points can actually impair estimation efficiency and accuracy, leading to wider confidence intervals and worse coverage probabilities.
- Beta regression is a natural fit: The bounded nature of biological responses makes beta regression a more appropriate statistical framework than standard linear regression.
- Robustness is key: The MDPDE approach within beta regression significantly improves the reliability of dose-response estimations when dealing with noisy or outlier-prone data.
- REAP democratizes advanced analysis: The development of a freely accessible web tool makes this powerful statistical methodology available to a broader scientific community, facilitating more accurate drug potency assessments.
Key Results
Simulation studies consistently showed that the robust beta regression approach (BRM) provided more accurate point estimates and narrower confidence intervals (CIs) compared to the standard linear regression model (LRM), especially when extreme data points were present. For instance, in scenarios with extreme values, BRM yielded CIs that were significantly narrower, indicating higher statistical power. The REAP application was demonstrated to effectively analyze real-world data, producing reasonable dose-response estimations for both auranofin in B-cell lymphoma cell lines and antiviral drugs against SARS-CoV-2.
Limitations and Future Work
The authors acknowledge that the current REAP implementation is based on the median-effect equation, which assumes a compound affects all cells. For scenarios where maximal effects differ, an Emax model might be more suitable. Additionally, the robust beta regression approach in REAP cannot handle values exactly equal to 0 or 1, requiring a data truncation algorithm. While this algorithm is effective, future work could focus on improving its efficiency in retaining information. The authors also suggest that the modeling framework could be extended to account for time-dependent cytotoxicity and to integrate into methods for identifying drug interaction effects, particularly in the context of multi-agent combination therapies.
Summary updated